SIGNA 7.0T receives US FDA clearance

GE Healthcare’s dedication to advancing neurological research and clinical translation with leading institutions around the world continues with the introduction of the newly FDA-cleared SIGNA™ 7.0T‡. The SIGNA™ 7.0T is designed to overcome the limitations of the majority of today’s clinical MR systems by leveraging the ultra-high field magnet technology within its core. With approximately five times higher field strength than most clinical systems, SIGNA™ 7.0T is designed to detect subtle structures that may be significant for clinicians and researchers alike. This new 60-centimeter bore system is designed to be a more powerful tool to image neurodegenerative diseases as well as extremities.

SIGNA™ 7.0T features UltraG gradient technology, GE’s most powerful, whole-body gradient coil, designed to meet the needs of ultra-high field imaging speed and resolution. This system features the familiarity of the SIGNA™Works applications platform so clinicians can use the latest state-of-the-art applications such as deep learning-based platform tools like AIR x™ brain for automated slice positioning and Silent MR imaging. In addition, SIGNA™ 7.0T is equipped with Precision RF transmit and receive architecture designed to enable improved image quality and research flexibility. (See related article Scientific discovery meets clinical translation at 7.0T.)